Profile: Threshold Pharmaceuticals Inc (THLD.OQ)
5.30USD
1 Aug 2013
$-0.12 (-2.21%)
$5.42
$5.48
$5.48
$5.26
125,670
127,854
$9.28
$3.95
Threshold Pharmaceuticals, Inc., incorporated on October 17, 2001, is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors and the bone marrows of some hematologic malignancies (blood cancers) as treatments for patients living with cancer. The Company's hypoxia activated prodrug (HAP) product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. The Company's focus is on product candidates for the treatment of patients with cancer. The Company's clinical development efforts are focused on TH-302, for which the Company entered a license and co-development agreement with Merck KGaA, on February 2, 2012, for worldwide development and commercialization. As of December 31, 2011, TH-302 is in Phase I, Phase II and Phase III clinical trials. The Company reported updated results from the Phase I monotherapy trial of TH-302, including updated data in patients with metastatic melanoma and small-cell lung cancer (SCLC).
The Company reported results from each of four Phase I/II combination therapy investigations of a chemotherapy agent plus TH-302 in solid tumors involving combining TH-302 with doxorubicin, gemcitabine, docetaxel and pemetrexed. In January 2011, the Company reported updated results from its Phase I/II combination clinical trials in patients with first-line pancreatic cancer treated with gemcitabine plus TH-302.
TH-302
The Company’s product candidate for cancer is TH-302, is a prodrug candidate discovered by the Company. TH-302 combines a two-nitroimidazole oxygen-sensing trigger with a masked deoxyribonucleic acid (DNA) crosslinker. Upon activation in oxygen deficient zones, TH-302 is converted selectively to the drug’s active form, dibromo isophosphoramide mustard, a potent alkylator. TH-302 focuses on levels of severe hypoxia that are found in tumors but are rare in normal tissues. After conversion to the active form of the drug, the hypoxic cells are exposed to high concentrations of released cytotoxic agent, which can also diffuse into the adjacent regions of the tumor. In March 2012, the Company had initiated a Phase I/II open label clinical trial of TH-302 in patients with relapsed/refractory multiple myeloma.
Glufosfamide
The Company has a license agreement with Eleison Pharmaceuticals, Inc. (Eleison). Pursuant to the agreement it granted Eleison worldwide rights to develop and commercialize glufosfamide for the treatment of cancer in humans and animals, and certain other uses. Under the agreement, Eleison is responsible for the development, manufacturing and marketing of glufosfamide.
The Company competes with AstraZeneca PLC, Genentech, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Bayer Pharmaceuticals, Hoffmann-LaRoche, Inc., Infinity Pharmaceuticals, Johnson & Johnson, Onyx Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Amgen Inc., Clovis Oncology, ImClone Systems, Inc., Millennium Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., Telik, Inc., Sanofi-Aventis U.S., Sunesis Pharmaceuticals, Inc., Plexxikon Inc., Celgene Corporation, Abraxis Bioscience Inc., ARIAD Pharmaceuticals, Inc. and ZIOPHARM Oncology, Inc.
Company Address
Threshold Pharmaceuticals Inc
Suite 300, 170 Harbor Way
SOUTH SAN FRANCISCO CA 94080
P: +1650.4748200
F: +1650.4742529
Company Web Links
| Name | Compensation |
|---|---|
Harold Selick |
1,556,770 |
Stewart Kroll |
602,815 |
Mark Matteucci |
585,221 |
Joel Fernandes |
434,108 |
Tillman Pearce |
565,569 |

